Taskbiz

07/02/2026

What Artificaial Inteligence is doing is phenomenal !

rentahuman.ai is the site and its hiring humans as worker to do its dirty works and what danger it can pose is evident from the job available (Please see the attachement and job number 3)

03/02/2026

https://youtube.com/shorts/9--xqrcrADs?feature=share

This is the Kappa Board made box with kappa tray and a huidden holder for Shilajeet bottle and rubbersied holder for Spoon

21/12/2025

AI Medical Diagnostic Pods: The Rise of Self-Service Healthcare

Healthcare is quietly stepping into the future with the emergence of AI-powered medical diagnostic pods—self-service health kiosks that offer quick check-ups without the need for a traditional clinic visit. These pods, now being deployed in countries like Saudi Arabia and tested in the US and Europe, can measure vital signs such as blood pressure, oxygen levels, temperature, and heart rate, and then use artificial intelligence to guide patients through basic health assessments.

What makes these pods especially promising is their ability to connect users instantly with doctors via teleconsultation. Placed in hospitals, pharmacies, workplaces, and even public spaces, they aim to improve healthcare access in remote or underserved areas and reduce overcrowding in clinics.

However, the journey hasn’t been without challenges. Some well-funded startups have failed, highlighting the importance of sustainable models, reliable technology, and patient trust. Researchers are also closely studying the accuracy, safety, and ethical implications of these systems—particularly around data privacy, AI bias, and the need for human oversight.

Experts agree on one thing: AI pods are not meant to replace doctors, but to support them. If implemented responsibly, they could become “micro-clinics” of the future—bringing basic healthcare closer to where people live and work.

The question now isn’t if this technology will grow, but how safely and effectively it will be integrated into everyday healthcare.

18/12/2025

NEWS

Here are the latest updates from the DCGI as of today:

• The DCGI has directed state authorities to begin planning for carrying out relevant inspections to enforce new manufacturing standards .

• The government has extended Rajeev Singh Raghuvanshi's tenure as DCGI by one year .

• Bharat Parenterals has received the DCGI nod for favipiravir oral suspension .

• AstraZeneca's Dapagliflozin tablets have received the DCGI nod for patients with chronic kidney disease .

• The CDSCO has directed all states and Union Territories to immediately launch a nationwide inspection drive to enforce the revised Schedule M of the Drugs and Cosmetics Rules, 1945 .

• The Subject Expert Committee (SEC) under the CDSCO has recommended approval for the updated package insert of Johnson and Johnson's Stelara .

• The SEC has granted approval to Zenvision Pharma to conduct a bioequivalence (BE) study on Rifaximin sachets .

• The SEC has approved Torrent Pharma to manufacture and market Prucalopride oral solution .

• The SEC has recommended the grant of permission for MSN Labs to manufacture and market Abiraterone Acetate 1000 mg tablets .

16/12/2025

More than 60% of India's 8,500 registered small and medium pharmaceutical units are facing potential closure by December 31, 2025, due to their inability to meet upgraded quality standards. The Central Drugs Standard Control Organisation (CDSCO) is enforcing revised "Schedule M" rules that align domestic manufacturing with global World Health Organization (WHO) standards to prevent public health crises linked to contaminated medicines.
Key Drivers of Potential Closures
Mandatory GMP Upgrades: The revised Schedule M rules require stricter quality controls, including pharmaceutical quality systems (PQS), computerized storage, and enhanced hygiene standards.
Missed Deadlines: While large firms (turnover >₹250 crore) complied by June 2024, MSMEs were given an extension to December 31, 2025. Only units that submitted a formal upgrade plan by May 2025 were eligible for this extension.
Financial & Technical Barriers: Upgrading facilities can cost several crores, an insurmountable expense for many single-facility units operating with thin margins. Many units also lack the technical expertise to implement validation protocols and digital batch records.
Expected Impacts
Market Share: The at-risk units account for approximately ₹75,000 crore of India’s ₹2.5 lakh crore domestic drug market.
Drug Shortages: Industry experts warn of nationwide shortages of essential, low-cost medicines, including:
Antibiotics and anti-inflammatory drugs.
Diabetes and anti-hypertensive medications.
Analgesics and cough/cold remedies.
Socio-Economic Consequences: Closures could lead to significant job losses and disrupt medicine security in low- and middle-income countries that rely on Indian exports.
Regulatory Stance
The Ministry of Health and Family Welfare and CDSCO have indicated there will be no further extensions beyond the December 2025 deadline. State drug controllers have already been directed to intensify inspections and take punitive action against non-compliant units.

11/12/2025

Indigo tantrums by Jaspal Bhatti

10/12/2025

News

• Zydus and Formycon have signed a licensing deal for Keytruda biosimilar in the US and Canada .

• The CDSCO has flagged a cough syrup as spurious and 112 drugs have failed quality tests .

• The government has extended Rajeev Singh Raghuvanshi's tenure as DCGI by one year .

• The DCGI has directed state authorities to begin planning for carrying out relevant inspections to enforce new manufacturing standards .

• Bharat Parenterals has received the DCGI nod for favipiravir oral suspension .

• AstraZeneca's Dapagliflozin tablets have received the DCGI nod for patients with chronic kidney disease .

26/11/2025

Latest NEWS & Nafithromycin

India’s pharma industry is witnessing major transformation, driven by cutting-edge R&D and technology adoption. EY reports that roughly 50% of Indian pharma firms are now exploring AI-driven solutions, with around 25% already deploying generative-AI in production — boosting efficiency, speeding drug discovery, and streamlining supply-chain and manufacturing processes.

Meanwhile, home-grown innovation is rising: Nafithromycin — launched in 2024 — is India’s first truly indigenous macrolide antibiotic tackling resistant bacterial pneumonia.
India Pharma Outlook

On the biotech front, the emergence of “Pharma 4.0” — integrating AI/ML, IoT-based manufacturing automation, big data analytics, and advanced supply-chain traceability — is helping firms shift from traditional generics to value-based, patient-centric therapies and biologics.

For pharma-marketers: this means an evolving opportunity — from promoting basic generics to positioning high-value, tech-enabled treatments, biologics and precision medicines.

24/11/2025

New Era in Obesity & Diabetes Treatment!

The field of medicine is being revolutionized by the new class of incretin mimetics, like semaglutide (Wegovy/Ozempic) and tirzepatide (Zepbound/Mounjaro). These drugs mimic gut hormones (GLP-1 and GIP) to control appetite and metabolism, offering unprecedented results.
• Tirzepatide (a dual-agonist) is now the benchmark, showing patients can lose up to 22% of their body weight in clinical trials, surpassing previous treatments.
• The next breakthrough is the triple-agonist, retatrutide, which in Phase 2 trials led to over 24% weight loss.
• Beyond weight: These treatments are increasingly proven to significantly reduce the risk of major cardiovascular events and show promise for treating heart failure and liver disease (MASH).
These advancements are redefining obesity as a manageable chronic disease.

23/11/2025

Sweden’s ‘Plaque-Clearing Nanobots’ Viral Claims Questioned; India Awaits Real Human Trial Data

Swedish nanobot research has sparked worldwide excitement, with viral posts claiming DNA-based nanobots can dissolve arterial plaque in just 15–20 minutes, eliminating the need for angioplasty or bypass surgery. However, a closer look reveals that these claims are not supported by any verified human clinical trial.

Karolinska Institutet in Sweden has indeed published promising work on DNA-based nanorobots capable of targeting specific cells in laboratory and animal models. These nanostructures can carry enzymes or therapeutic molecules and release them at targeted sites. But as of now, no peer-reviewed study shows human patients being cured of coronary artery disease using nanobots, nor any large clinical trial clearing plaque in minutes.

India’s scientific community is also actively working in this space. IIT Guwahati, IISER Pune, and several medical research centres are developing nanoparticles that can detect early atherosclerosis or deliver anti-inflammatory drugs directly to plaque sites. Still, this research is at the preclinical or early experimental stage, far from human-ready treatments.

For any nanomedicine therapy to be used clinically in India, it must comply with the country’s strict regulatory framework. The Department of Biotechnology (DBT), Indian Council of Medical Research (ICMR), and CDSCO have established detailed Nanopharmaceutical Evaluation Guidelines (2019). These require extensive animal safety studies, toxicology reports, pharmacokinetics, and multi-phase human clinical trials registered under the Clinical Trials Registry–India (CTRI).

Experts say that if future research—whether from Sweden, India, or anywhere else—successfully demonstrates safe and effective plaque-clearing nanobots in humans, the technology could transform cardiac care in India. With millions of Indians undergoing angioplasty or bypass annually, a minimally invasive nanotech treatment could dramatically lower risk, cost, and recovery time.

For now, however, the “15-minute artery cure” remains unverified.

19/11/2025

News today

• DCGI Orders Nationwide GMP Inspection Drive to Enforce Revised Schedule M .

• Sanofi's Tetraxim Vaccine Gets CDSCO Panel Nod for Expanded Indication .

• Ziller Medical Denied Manufacturing Nod for Cervical Cerclage Pessary Over Inadequate Safety Data .

• CDSCO Panel Approves Updated Package Insert for Johnson and Johnson's Stelara .

• CDSCO Panel Approves Updated Package Insert for Takeda's Vedolizumab .

• Dr. Reddy’s gets nod to make generic semaglutide for weight loss .

• Bharat Parenterals gets DCGI nod for favipiravir oral suspension .

• AstraZeneca's Dapagliflozin tablets get DCGI nod for patients with chronic kidney disease .

• Mylan gets DCGI nod for remdesivir in India, to launch at Rs 4,800 per vial .

• Serum Institute gets DCGI's nod to manufacture Sputnik V in India for test, analysis .